Teva Sues FDA to Block Generic Copaxone 2014-05-09 18:18:20.585 GMT
By Courtney Dentch May 9 (Bloomberg) -- Teva claims FDA fails to respond to request for generic trials; patent protection for Copaxone expires on May 24.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.